Merck is spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company (“NewCo”)
Materials and Resources
Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
KENILWORTH, N.J., May 3, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will host Organon management at a meeting with the investment community. Management will detail plans for how Organon is expected to drive sustainable growth and shareholder value as a standalone company.
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
KENILWORTH, N.J. & MENLO PARK, Calif., March 30, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death.¹ The transaction is expected to close after Organon has spun off from Merck as a standalone publicly traded company.
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.
KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission (“SEC”) in connection with the intended spinoff of its women’s health, biosimilars and established brands businesses into a standalone, publicly-traded company, Organon. Organon will register its common stock under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”).
The Form 10 includes detailed information about Organon, such as historic financial information, as well as a description of Organon’s business and strategy and other legal and financial disclosures.
A copy of the Form 10 is available on the SEC website at www.sec.gov and can also be viewed on www.merck.com/investors/sec-filings.
Merck Announces Appointment of Organon & Co. General Counsel
KENILWORTH, N.J., July 8, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Deborah H. Telman as General Counsel for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses.
In her new role, Deb will act as senior legal advisor to the Board of Directors, Chief Executive Officer and senior management and will be responsible for the company’s worldwide legal affairs, compliance and global environmental health & safety. She will join Organon from Sorrento Therapeutics where she served as Senior Vice President, General Counsel and Corporate Secretary leading the legal, compliance, human resource and quality functions. Deb has spent more than 20 years in senior executive roles at several global companies including Abbott, Johnson Controls and Boeing. She also brings deep experience in mergers and acquisitions, including a major pharmaceutical spinoff with Abbott at the time of its spin from AbbVie.
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
KENILWORTH, N.J., May 18, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Matthew Walsh and Rachel Stahler as Chief Financial Officer and Chief Information Officer, respectively, for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses.
In his new role at Organon, Matt will be responsible for the development and execution of the company’s overall financial strategy, and will oversee corporate financial planning, tax, audit, treasury, investor relations and business development. He will join Organon from Allergan where he served as Executive Vice President (EVP) and Chief Financial Officer (CFO). A seasoned finance executive with over 15 years of public company CFO experience, Matt has notable expertise in mergers and acquisitions, including 11 acquisitions and integrations and five divestitures during his nine-year tenure at Catalent where he served as EVP, CFO.
Merck Announces Organon & Co. as New Company Name for Planned Spinoff
KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses.
Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. The Organon name has strong brand equity and engenders great respect among health care professionals for its dedication and innovation in women’s health.
KENILWORTH, N.J., Feb. 5, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its intention to spin-off products from its Women’s Health, trusted Legacy Brands, and Biosimilars businesses into a new, yet-to-be-named, independent, publicly traded company. The spinoff will allow both management teams to drive increased responsiveness to the particular needs of their patients and customers and achieve faster growth through focused and fit-for-purpose operating models.
Merck will continue to benefit from strong growth across its current key pillars of Oncology, Vaccines, Hospital and Animal Health, while remaining fully committed to investing in research and development in pursuit of breakthrough innovations across all areas of science and to driving value from its deep late-stage pipeline. As a premier research-intensive biopharmaceutical company, Merck will continue its pursuit to advance the prevention and treatment of diseases that threaten people and communities around the world.